nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.09.2007 | Original Article

Determination of tumour hypoxia with the PET tracer [¹⁸F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model

verfasst von: Nicolas Christian, Anne Bol, Marc De Bast, Daniel Labar, John Lee, Pierre Mahy, Vincent Grégoire

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 9/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The 2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)acetamide (EF3) is a 2-nitroimidazole derivative which undergoes bioreductive activation under hypoxic conditions. Using the PET tracer [¹⁸F]EF3 in mice, tumour-to-muscle ratios ranging from 1.3 to 3.5 were observed. This study investigated the impact of various interventions aimed at increasing [¹⁸F]EF3 elimination, thus potentially increasing the tumour-to-noise ratio in mice, by increasing the renal filtration rate (spironolactone, furosemide), decreasing tubular re-absorption (metronidazole, ornidazole, amino acid solution) or stimulating gastro-intestinal elimination (phenobarbital).

Methods

C3H mice were injected i.v. with an average of 12.95 MBq of [¹⁸F]EF3. Drugs were injected i.v. 15 min before the tracer or daily 4 days prior to the experiment (phenobarbital). Anaesthetised mice were imaged from 30 to 300 min with a dedicated animal PET (Mosaic, Philips). Regions of interest were delineated around the tumour, bladder, heart, liver and leg muscle. Radioactivity was expressed as a percentage of injected activity per gram of tissue.

Results

Ornidazole decreased the urinary excretion and increased the liver uptake of [¹⁸F]EF3, but without causing any changes in the other organs. Phenobarbital significantly increased the liver concentration and decreased radioactivity in blood and muscle without affecting the tracer uptake in tumour. Consequently, a small but non-significant increase in tumour-to-noise ratio was observed. Although some effects were observed with other drugs, they did not modify the tumour-to-noise ratio.

Conclusion

Only phenobarbital induced a trend toward an increased tumour-to-noise ratio that could possibly be tested in the clinical situation.

Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978;37:302–6.

Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–15.PubMed

Fyles AW, Milosevic M, Wong R, Kavanagh MC, Pintilie M, Sun A, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149–56.PubMedCrossRef

Hockel M, Knoop C, Schlenger K, Vorndran B, Baussmann E, Mitze M, et al. Intratumoral pO₂ predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45–50.PubMedCrossRef

Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.PubMed

Hodgkiss RJ. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 1998;13:687–702.PubMed

Sorensen M, Horsman MR, Cumming P, Munk OL, Keiding S. Effect of intratumoral heterogeneity in oxygenation status on FMISO PET, autoradiography, and electrode pO₂ measurements in murine tumors. Int J Radiat Oncol Biol Phys 2005;62:854–61.PubMedCrossRef

Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [¹⁸F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001;9:665–75.PubMedCrossRef

Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995;194:795–800.PubMed

10.

Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [¹⁸F]EF1. J Nucl Med 2000;41:327–36.PubMed

11.

Ziemer LS, Evans SM, Kachur AV, Shuman AL, Cardi CA, Jenkins WT, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole [¹⁸F]EF5. Eur J Nucl Med Mol Imaging 2003;30:259–66.PubMedCrossRef

12.

Mahy P, De Bast M, Leveque PH, Gillart J, Labar D, Marchand J, et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)-N-(3,3,3-[¹⁸F]trifluoropropyl)acetamide, [¹⁸F]EF3. Eur J Nucl Med Mol Imaging 2004;31:1263–72.PubMedCrossRef

13.

Mahy P, De Bast M, Gillart J, Labar D, Gregoire V. Detection of tumour hypoxia: comparison between EF5 adducts and [¹⁸F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006;33:553–6.PubMedCrossRef

14.

Akel G, Canal P, Soula G. Renal elimination of the hypoxic cell radiosensitizer misonidazole in Wistar rats: influence of some drugs on its excretion. Eur J Drug Metab Pharmacokinet 1985;10:181–7.PubMedCrossRef

15.

de Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, et al. Megalin is essential for renal proximal tubule reabsorption of ¹¹¹In-DTPA-octreotide. J Nucl Med 2005;46:1696–700.PubMed

16.

Barone R, Pauwels S, De Camps J, Krenning EP, Kvols LK, Smith MC, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant 2004;19:2275–81.PubMedCrossRef

17.

Schuetz EG. Induction of cytochromes P450. Curr Drug Metab 2001;2:139–47.PubMedCrossRef

18.

Milas L, Hunter N, Mason K, Withers HR. Immunological resistance to pulmonary metastases in C3Hf-Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res 1974;34:61–71.PubMed

19.

Surti S, Karp JS, Perkins AE, Cardi CA, Daube-Witherspoon ME, Kuhn A, et al. Imaging performance of A-PET: a small animal PET camera. IEEE Transactions on Medical Imaging 2005;24:844–52.CrossRef

20.

Workman P, Brown JM. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol 1981;6:39–49.PubMedCrossRef

21.

Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 1999;277:H1967–74.PubMed

22.

Stypinski D, Wiebe LI, Tam YK, Mercer JR, McEwan AJ. Effects of methoxyflurane anesthesia on the pharmacokinetics of ¹²⁵I-IAZA in Sprague-Dawley rats. Nucl Med Biol 1999;26:959–65.PubMedCrossRef

Titel: Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model
verfasst von: Nicolas Christian
Anne Bol
Marc De Bast
Daniel Labar
John Lee
Pierre Mahy
Vincent Grégoire
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 9/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0376-7

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2007

Regional CBF changes in Parkinson’s disease: a correlation with motor dysfunction

Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies

PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment?

Multi-modality imaging on track

Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer’s disease using FDG-PET and 3D-SSP